FY2024 EPS Estimates for PepGen Increased by Leerink Partnrs

PepGen Inc. (NASDAQ:PEPG) – Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for PepGen in a research note issued on Sunday, November 10th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($2.91) for the year, up from their prior forecast of ($3.37). The consensus estimate for PepGen’s current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for PepGen’s Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.76) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.27) EPS and FY2026 earnings at ($2.98) EPS.

Several other equities analysts have also recently weighed in on PEPG. Bank of America cut PepGen from a “buy” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a report on Wednesday, July 31st. Wedbush reduced their price target on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of PepGen in a report on Friday, November 8th.

PepGen Trading Up 0.2 %

Shares of PepGen stock opened at $4.55 on Wednesday. PepGen has a 12 month low of $3.81 and a 12 month high of $19.30. The company has a market capitalization of $148.33 million, a PE ratio of -1.53 and a beta of 1.76. The stock’s fifty day simple moving average is $8.21 and its 200 day simple moving average is $12.07.

Institutional Trading of PepGen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of PepGen during the 1st quarter worth about $30,000. Point72 DIFC Ltd bought a new stake in PepGen during the second quarter worth about $42,000. Allspring Global Investments Holdings LLC acquired a new position in PepGen during the third quarter valued at approximately $95,000. Renaissance Technologies LLC bought a new position in PepGen in the second quarter valued at approximately $192,000. Finally, Marshall Wace LLP bought a new position in PepGen in the second quarter valued at approximately $196,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.